APA (7th ed.) Citation

LMY, G., SPH, v. d. B., AA, T., MT, W., EC, T., NIL, D., . . . ZLE, v. K. (2026). Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis. Frontiers in immunology, 17, 1796273. https://doi.org/10.3389/fimmu.2026.1796273

Chicago Style (17th ed.) Citation

LMY, Gelissen, et al. "Clinical Implications of Natalizumab Fab-arm Exchange in Patients with Multiple Sclerosis." Frontiers in Immunology 17 (2026): 1796273. https://doi.org/10.3389/fimmu.2026.1796273.

MLA (9th ed.) Citation

LMY, Gelissen, et al. "Clinical Implications of Natalizumab Fab-arm Exchange in Patients with Multiple Sclerosis." Frontiers in Immunology, vol. 17, 2026, p. 1796273, https://doi.org/10.3389/fimmu.2026.1796273.